Genito-urinary Cancer

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

PSAD-based triage, particularly at ≥0.15 ng/mL/cc, showed superior diagnostic utility and may support safe biopsy deferral in selected cases. Prospective validation in broader non-referral settings is warranted.

In conclusion, curcumin shows great promise in improving prostate cancer treatment by targeting key cancer pathways and enhancing the effects of existing therapies. While its potential is clear, further clinical studies are needed to refine its use and ensure its effectiveness in real-world applications.

Despite a history of recurrent urinary tract infections (UTIs) associated with mono-J catheters, the frequency of UTIs did not increase during therapy with IFX. This case indicates that infliximab may represent an effective therapeutic option for non-CD-related fistulas when there are no other therapeutic options available.

This study is the first to reveal PAH as a metabolic immunomodulator and an independent prognostic factor in postoperative PC patients. PAH may affect prostate cancer outcomes by altering the tumor microenvironment.

Biological evaluation identified compound 39 as an active degrader that induced substantial AR degradation in LNCaP prostate cancer cells. This work supports the feasibility of recruiting HSP70 for TPD and provides a molecular tool for AR-degradation research, thereby expanding the TPD toolbox for future drug discovery.

Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.

P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial primary completion date: Jun 2026 --> Nov 2026

Although HER2-targeted therapies, such as trastuzumab deruxtecan, have shown promising results in HER2-positive bladder cancer, optimal immunohistochemistry (IHC) scoring criteria for urothelial carcinoma remain unclear...Upper GI and breast scoring criteria yield divergent scores in a significant subset of urothelial carcinomas, potentially affecting eligibility for targeted therapy. Associations with histologic subtype and metastatic site support disease-specific diagnostic and therapeutic strategies.

P=N/A, N=589, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> Nov 2025 | Trial primary completion date: Jan 2027 --> Nov 2025

P2, N=30, Not yet recruiting, Deepak Kilari | Trial completion date: Dec 2027 --> Jul 2029 | Trial primary completion date: Dec 2026 --> Jul 2028